Morning Overview on MSN
Common gene variant may raise Alzheimer’s risk; researchers eye gene therapy
A genetic variant carried by at least one-fifth of the population may do far more than raise the odds of developing Alzheimer ...
Forbes contributors publish independent expert analyses and insights. A patient in a late-stage gene editing trial for a rare heart condition died from fatal liver complications after receiving an ...
Shares of Sarepta Therapeutics plunged more than 30% on Friday as the future of its approved gene therapy treatment appeared at risk. The Food and Drug Administration will request that the company ...
Ryuji Morizane, MD, PhD, of the Department of Medicine at Massachusetts General Hospital, is the senior/corresponding author of a new paper published in Signal Transduction and Targeted Therapy, "AAV ...
Pharmaceutical Technology on MSN
Huntington’s gene therapy research has reached a turning point, expert says
An expert involved in the first successful gene therapy trial for Huntington's Disease discusses the trial results and ...
The year 2023 marked a significant milestone for the treatment of sickle cell disease (SCD), with the approval of two gene therapies shown to help reduce the pain experienced by people with this ...
The last available hemophilia gene therapy is temporarily unavailable, according to CSL Behring. | The company is working ...
With promise to slow aging and cure some types of cancer, a new gene therapy presents cost and access hurdles for CT patients ...
What Is Waskyra, and Why Does It Matter? Waskyra (etuvetidigene autotemcel) is a new gene therapy approved to treat Wiskott-Aldrich syndrome (WAS), a rare inherited condition that affects the immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results